# CD80 (B7-1)

Source: https://onco.cc/targets/cd80/  
OnCo record `cd80` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

B7-1 is a molecule on antigen-presenting cells that gives T cells their go signal through CD28, but it also feeds the CTLA-4 brake and can pair with PD-L1. Anti-PD-L1 antibodies such as sugemalimab and adebrelimab are built to stop PD-L1 binding both PD-1 and B7-1.

## Summary

CD80 (chromosome 3q13.33), also called B7-1, is an immunoglobulin-superfamily costimulatory ligand that acts as the primary auxiliary signal for naive T cells by binding CD28, activating NF-kappa-B and MAPK and raising cytokine production and, through PI3K/AKT, T-cell glucose metabolism; it also binds CTLA-4, a decoy receptor that blocks CD28-mediated priming, and regulates PD-L1/PD-1 interactions (UniProt P33681). In OnCo it appears in the mechanism of the PD-L1 antibodies adebrelimab and sugemalimab, which block PD-L1 binding to PD-1 and to B7-1, and in the mechanism of ipilimumab, which stops CTLA-4 from outcompeting CD28 for B7 ligands during priming.

## Fields

- Kind: Target
- Last checked: 2026-09-22
- Also known as: B7-1; B7.1; CD28LG; CD80 molecule
- Tags: wave5-target
- Symbol: CD80
- Class: checkpoint
- Biology: The same ligand serves an accelerator (CD28) and a brake (CTLA-4), which is why CTLA-4 blockade increases T-cell priming. PD-L1 antibodies that also free B7-1 restore CD28 costimulation as well as lifting the PD-1 brake.
- Where found: Dendritic cells, macrophages and activated B cells; Small-cell lung cancer (adebrelimab) and NSCLC and peripheral T-cell lymphoma (sugemalimab) populations

## Notes

- Prevalence not recorded in this wave: HGNC and UniProt carry no positivity rates and no other source was consulted.

## Sources

- HGNC HGNC:1700: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1700
- UniProt P33681: https://www.uniprot.org/uniprotkb/P33681/entry
- NCBI Gene 941: https://www.ncbi.nlm.nih.gov/gene/941

## Connected records

- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Sugemalimab](https://onco.cc/drugs/sugemalimab/), [TQB2450](https://onco.cc/drugs/tqb2450/)
- targets: [CD28](https://onco.cc/targets/cd28/), [CTLA-4](https://onco.cc/targets/ctla4/), [PD-L1](https://onco.cc/targets/pdl1/)
- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- pathways: [PD-1 / PD-L1 immune checkpoint & T-cell activation](https://onco.cc/pathways/pd1-checkpoint/), [The cancer-immunity cycle](https://onco.cc/pathways/cancer-immunity-cycle/)

---
JSON: https://onco.cc/api/v1/entities/cd80.json